[{"orgOrder":0,"company":"Light Horse Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Light Horse Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Light Horse Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Light Horse Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"Light Horse Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Light Horse Therapeutics","amount2":1.03,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.03,"dosageForm":"","sponsorNew":"Light Horse Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Light Horse Therapeutics \/ Novartis Pharmaceuticals Corporation"}]

Find Clinical Drug Pipeline Developments & Deals by Light Horse Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PharmScience R&D
                          Not Confirmed
                          PharmScience R&D
                          Not Confirmed

                          Details : The financing is intended to support the company’s discovery platform for small-molecule drug research, utilizing innovative approaches to address the underlying causes and life-threatening diseases.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 09, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Sponsor : Versant Ventures

                          Deal Size : $62.0 million

                          Deal Type : Series A Financing

                          blank

                          02

                          PharmScience R&D
                          Not Confirmed
                          PharmScience R&D
                          Not Confirmed

                          Details : The collaboration between Novartis and Light Horse offers a remarkable opportunity to utilize a genetic screening platform and proprietary chemical libraries to develop innovative cancer treatments.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : $25.0 million

                          January 09, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Sponsor : Novartis Pharmaceuticals Corporation

                          Deal Size : $1,025.0 million

                          Deal Type : Collaboration

                          blank